Children's Oncology Group's 2013 blueprint for research: Bone tumors
Open accessAbstract
In the US, approximately 650 children are diagnosed with osteosarcoma and Ewing sarcoma (ES) each year. Five‐year survival ranges from 65% to 75% for localized disease and <30% for patients with metastases. Recent findings include interval‐compressed five drug chemotherapy improves survival with localized ES. In osteosarcoma a large international trial investigating the addition of ifosfamide/etoposide or interferon to standard therapy has completed accrual. For ES an ongoing trial explores the addition of cyclophosphamide/topotecan to interval‐compressed chemotherapy. Trials planned by the Children's Oncology Group will investigate new target(s) including IGF‐1R and mTOR in ES, and RANKL and GD2 in osteosarcoma. Pediatr Blood Cancer 2013; 60: 1009–1015. © 2012 Wiley Periodicals, Inc.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Children and adolescents with localized osteosarcoma have an overall survival of about 60% at baseline.
“At baseline, children and adolescents who present with localized osteosarcoma have an overall survival of ~60% 112 .”
From Osteosarcoma (2022) · cites this paper as [112]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 124 · Cited by 226
Research works printed but not linked: 1
- [110]Olmos D Postel-Vinay S Molife LR Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing’s sarcoma: A phase 1 expansion cohort study Lancer Oncol 2010 11 129 135 PMC2941877 20036194
- Authors
- Gorlick, R., Janeway, K., Lessnick, S., Randall, R. L., Marina, N., & on behalf of the COG Bone Tumor Committee
- Affiliations
- Albert Einstein College of Medicine (US)
- Dana-Farber/Boston Children's Cancer and Blood Disorders Center (US)
- University of Utah (US)
- Lucile Packard Children's Hospital (US)
- Corresponding author
- Gorlick, Richard
- Venue
- Pediatric Blood & Cancer
- Publisher
- Wiley
- Published
- 2012-12-19
- Volume
- 60
- Issue
- 6
- Pages
- 1009-1015
- ISSN
- 1545-5009 (ISSN-L)
- 1545-5017
- PMC
- PMC4610028
- OpenAlex
- W2011659954
- Cited by
- 226
- References
- 124
- Citations by year
- 2026: 9 · 2025: 23 · 2024: 18 · 2023: 22 · 2022: 19 · 2021: 17 · 2020: 19 · 2019: 11 · 2018: 13 · 2017: 14 · 2016: 20 · 2015: 17 · 2014: 21 · 2013: 3
- FWCI
- 2.23
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Pediatric Blood & Cancer (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (U01CA097452, U10CA098543)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Sarcoma Diagnosis and Treatment
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Acute Lymphoblastic Leukemia research
- Health Sciences › Medicine › Rheumatology › Bone Tumor Diagnosis and Treatments
- Keywords
- osteosarcoma, Ewing sarcoma, pediatric bone tumors, Children's Oncology Group, research priorities, interferon, IGF-1 receptor, mTOR, RANKL, GD2, metastatic disease
- MeSH terms
- Antineoplastic Combined Chemotherapy Protocols, Bone Neoplasms, Child, Clinical Trials as Topic, Humans, Research, Sarcoma, Ewing, Osteosarcoma
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
